USPTO Examiner RUSSEL JEFFREY E - Art Unit 1654

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18818974METHODS FOR STORING AND WARMING PURIFIED CORTICOTROPIN COMPOSITIONSAugust 2024December 2024Allow310NoNo
18733576ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEJune 2024September 2024Allow310NoNo
18634717METHODS FOR STORING AND WARMING PURIFIED CORTICOTROPIN COMPOSITIONSApril 2024August 2024Allow410YesNo
18598719IMMUNE CHECKPOINT INHIBITOR COMBINATIONSMarch 2024January 2025Allow1010NoNo
18444443COMPOSITIONS COMPRISING PHARMACEUTICALLY ACCEPTABLE SALTS OF GLUCAGON-LIKE PEPTIDE-1 ANALOGS AND USES THEREOFFebruary 2024December 2024Allow1010NoNo
18402138BIOACTIVE POLYMERIC DRESSING FOR ACCELERATED WOUND CLOSUREJanuary 2024November 2024Allow1110NoNo
18511852ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAMENovember 2023September 2024Allow1010NoNo
18495932METHODS FOR STORING AND WARMING PURIFIED CORTICOTROPIN COMPOSITIONSOctober 2023March 2024Allow520NoNo
18491099Reagents and methods for treating bacterial infectionOctober 2023November 2024Abandon1310NoNo
18461912Treatment of Rhinosinusitis with P-glycoprotein InhibitorsSeptember 2023November 2024Allow1520NoNo
18454855ANTIMICROBIAL PEPTIDE SPAMPCIN56-86 FROM SCYLLA PARAMAMOSAIN AND APPLICATIONS THEREOFAugust 2023June 2024Allow910NoNo
18450056INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDESAugust 2023August 2024Allow1210NoNo
18355223Controlled-Release PTH CompoundJuly 2023October 2023Allow310NoNo
18354076SOLUTION PHASE SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC SALTSJuly 2023December 2024Allow1730NoNo
18222170PROCESS FOR THE PREPARATION OF CYCLIC DEPSIPEPTIDESJuly 2023November 2024Allow1610NoNo
18340707ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEJune 2023November 2023Allow420YesNo
18327086SALTY TASTE ENHANCING PEPTIDE DERIVED FROM DRY-CURED HAM AND PREPARATION METHOD THEREOFJune 2023October 2023Allow510NoNo
18202103STABLE LIQUID COMPOSITIONS OF GLUCAGONMay 2023September 2024Allow1630YesNo
18320544PROCESS OF MAKING ABALOPARATIDEMay 2023August 2023Allow310YesNo
18308892NOVEL IL10 AGONISTS AND METHODS OF USE THEREOFApril 2023August 2024Allow1610NoNo
18139825USE OF CELL MEMBRANE-BOUND SIGNALING FACTORSApril 2023December 2024Allow1910NoNo
18193144ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAMEMarch 2023September 2023Allow610NoNo
18189997METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOFMarch 2023October 2024Abandon1910NoNo
18176372Dosage Regimen for a Controlled-Release PTH CompoundFebruary 2023November 2024Abandon2010NoNo
18158712USE OF BREMELANOTIDE IN PATIENTS WITH CONTROLLED HYPERTENSIONJanuary 2023August 2024Allow1820YesNo
18158002Methods and Compositions for Delivery of Biotin to MitochondriaJanuary 2023August 2023Allow710YesNo
18157752METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOFJanuary 2023July 2024Allow1810NoNo
18157756METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOFJanuary 2023July 2024Allow1810NoNo
18157739METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOFJanuary 2023September 2024Abandon2010NoNo
18157766METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOFJanuary 2023July 2024Allow1810YesNo
18154522SYSTEMS AND METHODS FOR MANUFACTURING A SILK FIBROIN SOLUTION AND POWDERS CONTAINING SILK FIBROINJanuary 2023November 2024Allow2220YesNo
18151155GLYCOPEPTIDE COMPOSITIONSJanuary 2023July 2024Allow1910YesNo
18082133BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELSDecember 2022July 2024Allow1921NoNo
18066396Methods and Compositions for Delivery of Biotin to MitochondriaDecember 2022May 2024Allow1750YesNo
18080057COMPOSITIONS AND METHODS FOR TREATING ALLERGIC INFLAMMATORY CONDITIONSDecember 2022September 2024Allow2111YesNo
18063294Controlled-Release PTH CompoundDecember 2022June 2023Allow620NoNo
18075971AMINO ACID COMPOSITIONS AND METHODS OF MANUFACTURING THE COMPOSITIONSDecember 2022September 2024Allow2120YesNo
18061084INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDESDecember 2022August 2024Abandon2110NoNo
18059718ANTI-INFECTIVE FORMULATIONSNovember 2022July 2024Allow2020NoNo
17954001MODIFIED COLLAGEN, METHODS OF MANUFACTURE THEREOFSeptember 2022November 2024Allow2611NoNo
17946447FORMULATIONS OF BIOLOGICS FOR INTRAVESICAL INSTILLATIONSeptember 2022March 2024Abandon1810NoNo
17946394Methods and Compositions for Delivery of Biotin to MitochondriaSeptember 2022February 2023Allow520YesNo
17932180SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOFSeptember 2022April 2024Abandon1901NoNo
17943532NON-CHROMATOGRAPHIC PURIFICATION OF MACROCYCLIC PEPTIDES BY A RESIN CATCH AND RELEASESeptember 2022February 2024Allow1701YesNo
17900450MATERIALS AND METHODS FOR TREATING FRIEDREICH'S ATAXIAAugust 2022August 2024Allow2420NoNo
17820337ENHANCEMENT OF CD47 BLOCKADE THERAPY BY PROTEASOME INHIBITORSAugust 2022April 2024Abandon2010NoNo
17883492COMPOSITIONS, METHODS, AND SYSTEMS FOR ORALLY ADMINISTRABLE AFFINITY-BASED PROTEINAugust 2022March 2024Allow1910YesNo
17881286ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACHAugust 2022June 2024Abandon2210NoNo
17874831WOUND TREATMENT CONTAINING COLLAGEN AND A GELATIN-REDUCING AGENT, AND METHOD FOR PROMOTING WOUND HEALINGJuly 2022January 2024Allow1820NoNo
17860642Glycopeptide CompositionsJuly 2022September 2022Allow310NoNo
17858629ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEJuly 2022June 2023Allow1230NoNo
17856729CELL-PROTECTING COMPOSITION CONTAINING CYCLO HISTIDINE-PROLINE AS ACTIVE INGREDIENTJuly 2022November 2023Allow1610NoNo
17850976COMPOSITIONS AND METHODS OF TREATING CANCER WITH GLYCOMIMETIC PEPTIDESJune 2022July 2024Abandon2520NoNo
17848180CNP PRODRUGSJune 2022September 2024Abandon2711NoNo
17847086PEPTIDOMIMETIC MACROCYCLESJune 2022April 2024Abandon2201NoNo
17844816Methods and Compositions for Delivery of Biotin to MitochondriaJune 2022January 2023Allow720YesNo
17832612FILL-FINISH PROCESS FOR PEPTIDE SOLUTIONSJune 2022February 2024Abandon2110YesNo
17756376IMMODULATOR PEPTIDES COVALENTLY MODIFIED WITH SMALL MOLECULESMay 2022June 2024Allow2510YesNo
17751451RAS INHIBITORY PEPTIDES AND USES THEREOFMay 2022April 2024Abandon2301NoNo
17707857KLK5 INHIBITORY PEPTIDEMarch 2022February 2024Allow2311NoNo
17705607METHOD FOR PREPARING PEPTIDESMarch 2022January 2024Allow2210NoNo
17673703CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODSFebruary 2022November 2024Abandon3311YesNo
17650570SYSTEMS AND METHODS FOR MANUFACTURING A SILK FIBROIN SOLUTION AND POWDERS CONTAINING SILK FIBROINFebruary 2022November 2022Allow911YesNo
17667330ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEFebruary 2022June 2022Allow520YesNo
17665947USE OF SELF-ASSEMBLING POLYPEPTIDES AS TISSUE ADHESIVESFebruary 2022August 2024Allow3031YesNo
17562861HER3 Peptides for Imaging and RadiotherapyDecember 2021January 2025Allow3631YesNo
17545217METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONSDecember 2021May 2024Allow2921NoNo
17545995CHLORIDE SALT OF TAT-NR2B9CDecember 2021October 2023Allow2220NoNo
17541019METHODS OF TREATMENT FOR BACTERIAL INFECTIONSDecember 2021March 2024Abandon2810NoNo
17540549VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORSDecember 2021December 2023Allow2420NoNo
17539727COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONSDecember 2021July 2023Allow1910NoNo
17526481CNP PRODRUGS WITH LARGE CARRIER MOIETIESNovember 2021March 2024Abandon2810NoNo
17518247AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOFNovember 2021July 2023Allow2000YesNo
17514469METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDUREOctober 2021November 2024Abandon3620NoYes
17606864LIPID-CONTROLLED RELEASE COMPOSITIONSOctober 2021December 2024Allow3710YesNo
17606699A YEAST-FERMENTED RECOMBINANT FIBRONECTIN PEPTIDE IN SMALL MOLECULE, AND ITS PREPARATION METHOD AND APPLICATIONS THEREOFOctober 2021December 2024Allow3820NoNo
17500735ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEOctober 2021June 2022Allow921YesNo
17499859INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDESOctober 2021May 2023Allow1910YesNo
17493551METHODS FOR REDUCING OXIDATIVE DAMAGEOctober 2021January 2025Abandon3920NoYes
17489495ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMESeptember 2021January 2022Allow410YesNo
17479101POLYPEPTIDES BINDING TO HUMAN COMPLEMENT C5September 2021January 2024Allow2810NoNo
17478027ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAMESeptember 2021February 2022Allow510NoNo
17474114METHODS OF TREATING OR PREVENTING STENT THROMBOSISSeptember 2021April 2024Abandon3120NoNo
17439163IRISIN IMPROVES PLACENTAL FUNCTION DURING PREGNANCYSeptember 2021December 2024Allow3920YesNo
17472574COMPOSITIONS AND METHODS FOR TREATING ACUTE RADIATION SYNDROMESeptember 2021September 2023Abandon2410NoNo
17470696AGENTS THAT INHIBIT NGLY1 AND METHODS OF USE THEREOFSeptember 2021September 2023Abandon2401NoNo
17469102DECARBOXYLATIVE CONJUGATE ADDITIONS AND APPLICATIONS THEREOFSeptember 2021January 2024Allow2820NoNo
17466661Methods and Compositions for Delivery of Biotin to MitochondriaSeptember 2021May 2022Allow911YesNo
17397796ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAMEAugust 2021September 2023Abandon2510NoNo
17395369VIRUS-LIKE PARTICLE CONJUGATES FOR DIAGNOSIS AND TREATMENT OF TUMORSAugust 2021September 2023Allow2510YesNo
17389571METHODS FOR TREATMENT OF COVID-19 SYNDROMEJuly 2021May 2023Allow2100YesNo
17443445METHODS FOR DISRUPTING BIOFILMSJuly 2021December 2023Abandon2910NoNo
17310186SYNTHESIS STRATEGY FOR GAP PROTECTING GROUPJuly 2021July 2023Allow2421YesNo
17373369SYNTHESIS METHOD OF CYCLOSPORINE DERIVATIVESJuly 2021August 2023Allow2510NoNo
17371475METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROMEJuly 2021August 2023Allow2520YesNo
17366463IMMUNE CHECKPOINT INHIBITOR COMBINATIONSJuly 2021July 2024Abandon3620YesNo
17364804Skin Protectant PasteJune 2021April 2023Abandon2210NoNo
17361087CIRCULAR TANDEM REPEAT PROTEINSJune 2021September 2023Allow2610YesNo
17351723Method For Treating Angiogenic Eye Disorders Using Vegf AntagonistsJune 2021January 2024Allow3120YesNo
17350723Heat Shock Protein-Binding Peptide Compositions And Methods Of Use ThereofJune 2021October 2023Abandon2810NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RUSSEL, JEFFREY E.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
2
Examiner Affirmed
2
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.9%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
81
Allowed After Appeal Filing
24
(29.6%)
Not Allowed After Appeal Filing
57
(70.4%)
Filing Benefit Percentile
44.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 29.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner RUSSEL, JEFFREY E - Prosecution Strategy Guide

Executive Summary

Examiner RUSSEL, JEFFREY E works in Art Unit 1654 and has examined 1,334 patent applications in our dataset. With an allowance rate of 69.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 29 months.

Allowance Patterns

Examiner RUSSEL, JEFFREY E's allowance rate of 69.8% places them in the 32% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by RUSSEL, JEFFREY E receive 1.72 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by RUSSEL, JEFFREY E is 29 months. This places the examiner in the 62% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +36.8% benefit to allowance rate for applications examined by RUSSEL, JEFFREY E. This interview benefit is in the 85% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 32.8% of applications are subsequently allowed. This success rate is in the 70% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 68.3% of cases where such amendments are filed. This entry rate is in the 91% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 96.4% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 96.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 74.7% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.9% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 15.3% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.